How a big biotech’s start-up gamble went wrong

0 Anmeldelser
0
Episode
151 of 270
Længde
23M
Sprog
Engelsk
Format
Kategori
Økonomi & Business

Illumina, the world’s biggest gene sequencing company, announced plans to buy cancer detection start-up Grail for $8bn while the biotech boom was in full swing. To Illumina, Grail looked like a potential gold mine. Until reality — and regulators — entered the picture. Three years and an activist investor campaign waged by Carl Icahn later, the FT’s US pharmaceutical correspondent Jamie Smyth explains the problems that have cropped up and what it means for both companies and their shareholders.

Clips from Illumina Inc / Seeking Alpha, Yahoo

- - - - - - - - - - - - - - - - - - - - - - - - - -

For further reading:

Carl Icahn takes aim at genome sequencer Illumina over Grail deal

Has Illumina taken the wrong path in its Grail quest?

Quick blood tests to spot cancer: will they help or harm patients?

- - - - - - - - - - - - - - - - - - - - - - - - - -

On Twitter, follow Jamie Smyth (@JamieSmythF) and Michela Tindera (@mtindera07)

Read a transcript of this episode on FT.com

Hosted on Acast. See acast.com/privacy for more information.


Lyt når som helst, hvor som helst

Nyd den ubegrænsede adgang til tusindvis af spændende e- og lydbøger - helt gratis

  • Lyt og læs så meget du har lyst til
  • Opdag et kæmpe bibliotek fyldt med fortællinger
  • Eksklusive titler + Mofibo Originals
  • Opsig når som helst
Prøv nu
DK - Details page - Device banner - 894x1036

Other podcasts you might like ...